Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
|
|
UROLOGIX INC (ULGX)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/20/2014 |
8-K
| Quarterly results|
Docs:
|
"Urologix, Inc. Statements of Operations Three Months Ended June 30, Twelve Months Ended June 30, 2014 2013 2014 2013 Sales $ 3,294 $ 4,184 $ 14,235 $ 16,590 Cost of goods sold 1,711 2,279 8,142 8,407 Gross profit 1,583 1,905 6,093 8,183 Costs and expenses: Sales and marketing 1,011 2,080 5,850 7,719 General and administrative 526 421 2,299 2,515 Research and development 344 514 1,625 2,269 Change in value of acquisition consideration — Impairment of goodwill 3,036 — 3,036 — Gain on demutualization — — — Impairment of identifiable intangible assets — 160 — 160 Medical device tax 51 65 223 106 Amortization expense 23 26 95 104 Total costs and expenses 4,991 3,187 13,023 12,105 Operating loss Interest expense Gain on debt extinguishment — 206 — 206 Foreign currency exchange gain/ 2 Loss..." |
|
| 05/07/2014 |
8-K
| Quarterly results|
Docs:
|
"Three Months Ended March 31, Nine Months Ended March 31, 2014 2013 2014 2013 Sales $ 3,356 $ 4,082 $ 10,941 $ 12,405 Cost of goods sold 2,507 2,056 6,431 6,127 Gross profit 849 2,026 4,510 6,278 Costs and expenses: Sales and marketing 1,313 1,915 4,839 5,639 General and administrative 527 711 1,773 2,094 Research and development 408 538 1,281 1,756 Change in value of acquisition consideration — Gain on demutualization — — Medical device tax 52 41 172 41 Amortization expense 28 26 72 78 Total costs and expenses 2,316 2,910 8,032 8,918 Operating loss Interest expense Foreign currency exchange gain/ 1 Loss before income taxes Income tax expense 18 17 46 48 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted average number of co..." |
|
| 02/05/2014 |
8-K
| Quarterly results|
Docs:
|
"Urologix, Inc. Statements of Operations Three Months Ended December 31, Six Months Ended December 31, 2013 2012 2013 2012 Sales $ 3,806 $ 4,354 $ 7,585 $ 8,324 Cost of goods sold 2,008 2,117 3,923 4,072 Gross profit 1,798 2,237 3,662 4,252 Costs and expenses: Sales and marketing 1,681 2,007 3,527 3,724 General and administrative 561 646 1,246 1,383 Research and development 452 602 874 1,218 Change in value of acquisition consideration Medical device tax 59 — 119 — Amortization expense 22 26 44 52 Total costs and expenses 2,690 3,066 5,717 6,008 Operating loss Interest expense Foreign currency exchange gain/ 1 2 2 Loss before income taxes Income tax expense 16 16 28 32 Net loss $ $ $ $ Net loss per common share--basic $ $ $ $ Net loss per common share--diluted $ $ $ $ Weighted avera..." |
|
| 04/27/2012 |
8-K
| Form 8-K - Current report |
| 01/25/2012 |
8-K
| Quarterly results |
| 05/03/2011 |
8-K
| Form 8-K - Current report |
| 01/26/2011 |
8-K
| Form 8-K - Current report |
| 11/04/2010 |
8-K
| Quarterly results |
| 08/25/2010 |
8-K
| Quarterly results |
| 08/29/2008 |
8-K
| Quarterly results |
|
|